Barclay Pearce Capital
- Jun 30, 2026
- 1 min read
ABSI - SomnoMed Limited (ASX:SOM): Fallen Angel, New Wings
Originally listed in 2004, SomnoMed (ASX:SOM) was once a rising name on the ASX. Although the company has endured a challenging period, it has regained momentum with new management implementing a strategic shift in the business that has strengthened both its financial performance and core operations.
We believe this has created a runway for the company to deliver sustained growth moving forward.
Gain Access to the Full Desk Note
Investor Highlights
-
Proven business with proprietary solutions – First company worldwide to provide clinically proven medical oral appliance therapy to over 1 million patients in over 20 countries globally.
-
Turnaround in progress – Consistent double-digit revenue growth (across quarterly, annual periods over pcp) and across all global jurisdictions. New management has returned the company to cash flow positive status.
- 22% Revenue Growth YoY in FY25 to $111.5m, exceeding market guidance range of a $7m-$9m increase.
- FY25 losses of -$0.58m, strong improvement from FY24 losses of -$13m. FY24 diluted EPS of -$0.10, improving to -$0.016 in FY25 following a pivot in operational strategy.
- Continued penetration into global markets - Products launched further into EU territories, including national tender wins in the Nordics and the U.K. Increases in manufacturing capacity by at least 25%, set for launch in FY26 which will increase SOM’s ability to scale effectively.
Share Link